Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PA-1-STK
- Development stage
- Phase 1
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intrapleural
01
Overview
PA-1-STK is a gene-modified ovarian carcinoma cell line designed to deliver the Herpes Simplex Virus thymidine kinase (HSV-tk) gene. It functions as a vaccine, intended to be administered intrapleurally in conjunction with ganciclovir. The delivered HSV-tk gene makes the target cells sensitive to ganciclovir, which is then converted into a toxic metabolite, leading to an antitumor effect, particularly in malignant mesothelioma.
- Other names
- PA-1-STK modified ovarian carcinoma vaccinePA1-STK modified ovarian carcinoma vaccinePA 1-STK modified ovarian carcinoma vaccineHSV-tk-gene-modified cell line PA-1-STK
02
Targets
HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))
Beyond the preview
Go deeper on PA-1-STK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PA-1-STK.